Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas

Blockade of the cell cycle at G2/M maximizes DNA alteration in response to therapy; improved oxygenation enhances the generation of reactive oxygen species during polytherapy; and increased vascularity facilitates synergy with radiation and chemotherapy by improving drug delivery.

Authors

John Rothman

Institutions

Pfizer (United States) (US)

Publication Details

Journal: Expert Review of Anticancer Therapy
Published: 2026-01-25
DOI: https://doi.org/10.1080/14737140.2026.2623045
Primary Topic: Effects of Radiation Exposure
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas

John Rothman

Jan 25, 2026

Expert Review of Anticancer Therapy

Effects of Radiation Exposure

article

Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas

John Rothman

January 25, 2026article en

Abstract

Expert Review of Anticancer Therapy

Pfizer (United States) (US)

Good health and well-being

Openalex Percentile: Top 80%

Effects of Radiation Exposure

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas — John Rothman · Expert Review of Anticancer Therapy (2026) | TGRS Research Map | TGRS